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The Lifecycle of an Evidence-Based Laboratory Practice
Guideline
Origin, Update, Affirmation, and Impact!
Raouf Nakhleh, MD; Patrick L. Fitzgibbons, MD; Jan A. Nowak, MD, PhD; Robert M. Najarian, MD; David F. Keren, MD;
Terence J. Colgan, MD, FRCPC, MIAC; Carol Colasacco, MLIS; Lisa A. Fatheree, BS, SCT(ASCP)
The College of American Pathologists (CAP) made astrategic decision 10 years ago to develop and publish
evidence-based laboratory practice guidelines (LPGs). As
the CAP had worked previously with the American Society
of Clinical Oncology (ASCO) to develop the HER2 breast
cancer guideline, the CAP Pathology and Laboratory
Quality Center (the Center) was officially launched in 2010
with the publication of the estrogen and progesterone
testing guideline. Since then, the Center has published 14
LPGs, with 9 more in progress at various stages of
development in partnership or collaboration with 20
different medical societies.1
Evidence-based LPGs are created with the expectation
that they will be adopted by laboratories. Ultimately,
improved patient care is the primary reason for developing
guidelines. We believe that we are succeeding in this
mission to improve laboratory practices, advance medicine,
and promote patient wellness and safety. A secondary
benefit has been to raise the profile of pathology and
laboratory medicine as leaders in advancing evidence-based
patient care. This article will describe the process the Center
uses to develop and maintain LPGs.
HOW ARE TOPICS SELECTED?
The Center is deliberate in soliciting topics from a wide
range of pathologists representing various subspecialties
and practice situations. Our focus has been in areas where
laboratories need guidance to assure appropriate testing.
Topics are carefully vetted and vigorously debated to ensure
that a proposed evidence-based guideline is practical,
timely, and desirable. Patient safety and a demonstration
of a practice gap in a particular area are among the primary
factors used for selection. Another factor that influences our
decision is the ability to focus a clinical question by using the
PI/TCO format (population, intervention/test, comparator,
and outcome)2,3 so that rational recommendations can be
articulated and easily adopted.
HOW IS A GUIDELINE DEVELOPED?
The Center follows rigorous procedures for guideline
development using standards outlined in the National
Academy of Medicine’s (formerly Institute of Medicine)
‘‘Clinical Practice Guidelines We Can Trust.’’4 There are 7
basic principles that have been defined for trustworthy
guidelines: (1) establish transparency, (2) manage conflicts
of interest, (3) establish multidisciplinary panel, (4) perform
systematic review, (5) rate the strength of recommendations,
(6) articulate recommendations, and (7) include external
review. Similar to laboratory standard operating procedures,
the Center has written procedures that addresses each one
of these standards and updates accordingly. The CAP is an
organizational member of the Guidelines International
Network (G-I-N) and strives to maintain current best
practices in guideline development.
WHAT HAPPENS TO A GUIDELINE
ONCE IT’S PUBLISHED?
The initiation of every new guideline project comes with
the recognition that the work of the project expert panel
does not end with publication. Important elements in every
guideline are the dissemination of the guideline, education
at national meetings, the creation of educational tools for
expected users, and some manner for monitoring its
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adoption and effectiveness. Guidelines are living documents
that have to keep up with changes in patient populations,
laboratory methods, and available knowledge. We are
committed to doing the research to understand how a
guideline affects practice and understanding the barriers and
facilitators to adoption. This is nicely demonstrated by work
investigating the adoption of recommendations for immu-
nohistochemical (IHC) assay validation; these recommen-
dations initially focused on HER2, but later expanded with a
more general guideline to include all predictive and non-
predictive markers.5,6 Soon after the initial release of the
ASCO-CAP HER2 Testing in Breast Cancer guideline,6 we
conducted a survey of laboratories to determine the
guideline’s impact on laboratory practices.7,8 At the same
time, others set out to prove that some recommendations
could be modified to make practice easier.9 One example is
the demonstration that fixation of tissue for greater than 48
hours was not detrimental to measurements of HER2
expression.9 All of this added knowledge was used to
update the guideline in 2013.10 This is the framework for
how guidelines are created and updated. The Center does
not have a direct role in setting accreditation or proficiency
testing requirements; however, the knowledge gathered by
the Center is shared openly with all CAP divisions. The
Laboratory Accreditation Program, independent of the
Center, may choose to create or change a checklist standard
if they believe it improves patient care.
In 2010 laboratories were surveyed regarding their
practices in validating predictive and nonpredictive IHC
markers other than HER2.11 This survey demonstrated a
significant gap in practice indicating the need for a
generalized guideline for initial analytic validation of IHC
assays. After publishing this LPG,5 another survey was
conducted to determine its effectiveness as well as to
identify possible barriers and facilitators to acceptance.12
This was valuable in gaining further knowledge that will be
used in future guideline updates. This work has been
supported by a 5-year cooperative grant from the Centers
for Disease Control and Prevention under award number
1U47OE000057.
HOW LONG DOES A GUIDELINE LAST?
The National Guideline Clearinghouse (NGC) criteria for
posting an LPG on their Web site state that the guideline
must have been developed, reviewed, or revised within the
past 5 years.13 At the Center, defined procedures have been
established to reassess each guideline every 4 years or earlier
if new evidence indicates an update is warranted. Using the
same methodology as the original guideline, and in agree-
ment with any partners/collaborators, the literature is
searched for new knowledge. To date, we have updated
guidelines for HER2 testing in breast cancer and molecular
testing for lung cancer patients (both soon to be published).
(Note added in proof: the updated molecular testing for lung
cancer patients guideline was published as an Early Online
Release on January 22, 2018.) We will soon update the
validation of whole slide imaging given the recent US Food
and Drug Administration approval of digital pathology
systems as a primary diagnostic modality.
WHAT HAPPENS TO A GUIDELINE IF THERE IS
NO NEW KNOWLEDGE?
Recently, the ‘‘Consensus Statement Effective Communi-
cation of Urgent Diagnoses and Significant, Unexpected
Diagnoses in Surgical Pathology and Cytopathology’’
published with the Association of Directors of Anatomic
and Surgical Pathology was examined for new research or
concepts that would lead to a change of the recommenda-
tions.14 We followed our defined procedure for this
assessment and finding no new evidence, we chose to
reaffirm this LPG. The documentation of this process was
then submitted to NGC and is posted as a reaffirmation.15
WHAT IS THE IMPACT OF THE CAP’S GUIDELINES?
The primary purpose of the guidelines is to promote
uniform, quality pathology and laboratory services based on
the best evidence available. The ultimate goal is to ensure
optimal patient care. There are secondary benefits to having
guidelines as well. The establishment of best practices for
pathologists allows for ready documentation of quality for
those agencies charged with such oversight, often linking
quality behaviors with reimbursement. The availability of
evidence-based guidelines has been immensely useful to
payers in acknowledging the importance and necessity for
certain services. That is of benefit not only to pathologists
and the institutions they work for, but for the patients who
need those services. Guideline collaboration is an example
of how the CAP as a whole is working together with other
organizations to solve problems for the benefit of patients.
Because of success with LPGs, other organizations look to
us to join forces on other patient care improvement projects.
Since their introduction, CAP guideline PDFs have been
downloaded more than 184,000 times and they have been
cited in the literature 8052 times in journals from 115
countries, demonstrating wide acceptance and interest, and
hopefully, overall adoption. We believe their main impact
has been in better testing processes and improved patient
care.
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